Timothy Hatlen
A5033366731- COVID-19 Clinical Research Studies
- SARS-CoV-2 and COVID-19 Research
- HIV/AIDS Research and Interventions
- Long-Term Effects of COVID-19
- HIV Research and Treatment
- HIV/AIDS drug development and treatment
- Cerebrospinal fluid and hydrocephalus
- SARS-CoV-2 detection and testing
- Bladder and Urothelial Cancer Treatments
- Antimicrobial Resistance in Staphylococcus
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Urinary Bladder and Prostate Research
- Spinal Dysraphism and Malformations
- Hepatitis C virus research
- Antifungal resistance and susceptibility
- Nail Diseases and Treatments
- Fungal Infections and Studies
- Urinary Tract Infections Management
- Streptococcal Infections and Treatments
- Parasitic infections in humans and animals
- Hernia repair and management
- Polyomavirus and related diseases
- Skin Diseases and Diabetes
- Dermatological and COVID-19 studies
- HIV-related health complications and treatments
Harbor–UCLA Medical Center
2017-2025
UCLA Medical Center
2017-2025
Los Angeles Medical Center
2020-2024
The Lundquist Institute
2018-2022
University of California, Los Angeles
2020-2022
Providence Sacred Heart Medical Center
2017
University of Washington
2009-2012
Seattle Children's Hospital
2010
Granulocyte-macrophage colony-stimulating factor (GM-CSF) and dysregulated myeloid cell responses are implicated in the pathophysiology severity of COVID-19.
Importance Current data identifying COVID-19 risk factors lack standardized outcomes and insufficiently control for confounders. Objective To identify associated with COVID-19, severe SARS-CoV-2 infection. Design, Setting, Participants This secondary cross-protocol analysis included 4 multicenter, international, randomized, blinded, placebo-controlled, vaccine efficacy trials harmonized protocols established by the Prevention Network. Individual-level from participants randomized to receive...
This is a retrospective review of all children with myelomeningocele (MMC) who were undergoing surgery for scoliosis at our institution.Our aim was to investigate possible correlations between poor nutritional indexes and/or positive urinary cultures before perioperative infection risk.Patients have secondary MMC been shown high rate infectious complications. Many found asymptomatic tact infections due their neurogenic bladder. There little literature on risk factors and ways prevent...
Ensovibep (MP0420) is a designed ankyrin repeat protein, novel class of engineered proteins, under investigation as treatment SARS-CoV-2 infection.To investigate if ensovibep, in addition to remdesivir and other standard care, improves clinical outcomes among patients hospitalized with COVID-19 compared care alone.Double-blind, randomized, placebo-controlled, trial. (ClinicalTrials.gov: NCT04501978).Multinational, multicenter trial.Adults COVID-19.Intravenous 600 mg, or placebo.Ensovibep was...
Abstract BACKGROUND Increasing age is a risk factor for COVID-19 severity and mortality; emerging science implicates GM-CSF dysregulated myeloid cell responses in the pathophysiology of severe COVID-19. METHODS We conducted large, global, double-blind, randomized, placebo-controlled study evaluating single 90 mg infusion otilimab (human anti-GM-CSF monoclonal) plus standard care adults hospitalized with respiratory failure systemic inflammation, stratified by clinical status. Primary outcome...
Programmable valves (PVs) for shunting CSF have increasingly replaced nonprogrammable (NPVs). There been only a few longer-term studies (≥ 5 years) conducted that compared the effectiveness of NPVs with PVs children hydrocephalus, and 1 study has reported as being favorable over PVs. The objective this retrospective was to compare long-term survival these 2 types shunt valves.The authors collected data all patients who underwent insertion or revision between January 1, 2000, December 31,...
Objective: To move closer to achieving the third target of UNAIDS 90-90-90 goals, we prospectively implemented a viral load (VL) champion (VLC) program aimed at enhancing VL monitoring and recognition treatment failure. Design: Three clinics in eThekwini, Kwa-Zulu Natal (low-, medium- high-volume, encompassing 9184 patients overall) were each assigned VLC. We employed descriptive analysis (chart audit) compare pre-intervention period 1-year post-intervention period. The number with test...
Abstract Background There is a paucity of outcome data in high-resource settings for cryptococcal meningitis (CM) persons living with HIV (PWH). Novel induction regimens, such as the first-line recommended regimen from World Health Organization, may reduce duration hospitalization and drug-associated adverse events similar treatment outcomes. However, these regimens were not compared to standard care used countries, leading reluctance change current practice. Randomized controlled trials...
Abstract Background Therapy related complications, morbidity and mortality are still problematic in treating pneumocystis jirovecii pneumonia (PJP) persons living with HIV (PWH) on antiretroviral therapy (ART). Our study aims to outline patient demographics hospital outcomes among PWH a safety-net during the contemporary ART era. Methods We retrospectively reviewed extracted data from inpatient encounters PJP between 2015-2022 at Los Angeles County, California Results identified 55 (58...
The impact on immunogenicity and efficacy of SARS-CoV-2 vaccination in people with prior COVID-19 could differ depending timing number doses. VATICO study randomized 66 hospitalized recovered individuals to receive either immediate or deferred vaccination, one two doses mRNA vaccines. We measured binding neutralizing antibodies against at enrollment longitudinally. Median (IQR) time from infection first was 68 (53–75) days the group, 151 (137–173) group. At week 48, vaccine did not influence...
Abstract Dolutegravir resistance is emerging in routine clinical contexts southern Africa, primarily patients with prior treatment experience failing dolutegravir-based antiretroviral therapy (ART). This potential issue was raised by The Nucleosides and Darunavir/Dolutegravir Africa trial that compared dolutegravir boosted protease inhibitor–based as second-line ART, which new observed at failure. However, recent data suggest also risk are who were transitioned to from non-nucleoside reverse...
Human adenovirus (HAdV) is a linear, non-enveloped, double-stranded DNA virus that typically causes mild respiratory, gastrointestinal, and conjunctival illnesses in healthy persons.1 However, HAdV may cause more severe infection immunocompromised patients, especially those who have received organ transplants. In kidney transplant recipients, urinary tract the most frequently reported manifestation at 4.8%, with rare dissemination.2,3 surveillance study, 6.5% of recipients will positive...
Although corticosteroid therapy is the standard of care for all patients hospitalized with severe coronavirus disease 2019 (COVID-19), studies demonstrating mortality–benefit ratio corticosteroids were limited to fully evaluate their adverse effects. To determine severity corticosteroid-induced hyperglycemia in and without diabetes mellitus, we retrospectively collected data from medical records COVID-19 before after care. Corticosteroid-induced was more than those diabetes. Additionally,...
Fungal endocarditis remains an uncommon clinical diagnosis, though is likely to become more frequent due the global increase in transplantations and cardiac valvular surgery. A case of prosthetic valve Aspergillus fumigatus described that was diagnosed with serologic fungal markers confirmed positive blood cultures, finding.
Identification of patients on antiretroviral therapy (ART) with virological failure (VF) and the response in public health sector remain significant challenges. We previously reported improvement routine viral load (VL) monitoring after ART commencement through a system-strengthening, nurse-led 'VL champion' programme as part multidisciplinary team three clinics Durban, South Africa.To report impact VL champion model adapted to identify, support co-ordinate management individuals VF...
Background: Tixagevimab/cilgavimab is a neutralising monoclonal antibody combination hypothesized to improve outcomes for hospitalised COVID-19 patients.Methods: In phase 3, blinded, randomised, placebo-controlled trial, adults at 81 sites on four continents were assigned receive intravenous tixagevimab 300 mg/cilgavimab mg or placebo, in addition remdesivir and other standard care. The primary outcome was time sustained recovery through day 90, defined as 14 consecutive days home after...
Cryptococcal meningitis accounts for an estimated 25% of AIDS-associated mortality in sub-Saharan Africa. Accumulating animal and human evidence suggest that a higher, more fungicidal, dose fluconazole during consolidation therapy could be effective controlling residual infection may help significantly reduce posthospitalization mortality. Although the potential toxicity is low, use at 800 mg/day requires examination randomized clinical trial. In interim, within countries where postdischarge...
Neutralizing monoclonal antibodies (nmAbs) failed to show clear benefit for hospitalized patients with coronavirus disease 2019 (COVID-19). Dynamics of virologic and immunologic biomarkers remain poorly understood.
Biomarker guided therapy could improve management of COVID-19 inpatients. Although some results indicate that antibody tests are prognostic, little is known about patient using point-of-care (POC) tests. inpatients were recruited to evaluate 2 POC tests: LumiraDX and RightSign. Ease use data was collected. Blood also collected for centralized testing established assays (GenScript cPass). A nested case-control study assessed if conducted on stored specimens predictive time sustained recovery,...